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Background: Although optic neuritis (ON) is a defining feature of neuromyelitis optica (NMO), appropriate animal
models of NMO ON are lacking. Most NMO patients are seropositive for immunoglobulin G autoantibodies
(NMO-IgG) against the astrocyte water channel aquaporin-4 (AQP4).
Methods: Several approaches were tested to develop a robust, passive-transfer mouse model of NMO ON, including
NMO-IgG and complement delivery by: (i) retrobulbar infusion; (ii) intravitreal injection; (iii) a single intracranial injection
near the optic chiasm; and (iv) 3-days continuous intracranial infusion near the optic chiasm.
Results: Little ON or retinal pathology was seen using approaches (i) to (iii). Using approach (iv), however, optic nerves
showed characteristic NMO pathology, with loss of AQP4 and glial fibrillary acidic protein immunoreactivity, granulocyte
and macrophage infiltration, deposition of activated complement, demyelination and axonal injury. Even more
extensive pathology was created in mice lacking complement inhibitor protein CD59, or using a genetically
modified NMO-IgG with enhanced complement effector function, including significant loss of retinal ganglion
cells. In control studies, optic nerve pathology was absent in treated AQP4-deficient mice, or in wild-type mice
receiving control (non-NMO) IgG and complement.
Conclusion: Passive transfer of NMO-IgG and complement by continuous infusion near the optic chiasm in mice is
sufficient to produce ON with characteristic NMO pathology. The mouse model of NMO ON should be useful in further
studies of NMO pathogenesis mechanisms and therapeutics.
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Neuromyelitis optica (NMO) is an autoimmune inflamma-
tory disease of the central nervous system that causes de-
myelinating lesions in optic nerve and spinal cord, leading
to loss of visual and motor function [1-3]. A specific fea-
ture of NMO is the presence of serum immunoglobulin G
(IgG) autoantibodies (NMO-IgG) against astrocyte water
channel aquaporin-4 (AQP4) [4,5]. NMO pathogenesis is
thought to involve NMO-IgG binding to AQP4 on astro-
cytes, which causes complement- and cell-mediated astro-
cyte cytotoxicity, inflammation, and blood–brain barrier* Correspondence: Alan.Verkman@ucsf.edu
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article, unless otherwise stated.(BBB) disruption, with secondary oligodendrocyte and
neuron damage [6-8]. Current therapies of NMO include
general immunosuppression, B-cell depletion and plasma
exchange [9,10].
Although optic neuritis (ON) with permanent loss of
vision is a major clinical feature of NMO [11-13], ad-
equate models of NMO ON are lacking. The particular
sensitivity of the optic nerve in NMO suggests the need
to study disease mechanisms and treatment responses in
optic nerve-specific NMO models. Disease-relevant ani-
mal models of NMO are important for investigating
pathogenesis mechanisms, such as the role of inflamma-
tory effector cells [14-16] and for testing of potential
therapeutics such as antibodies targeting AQP4 [17] or
complement [18,19]. The original models of NMO involvedCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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roinflammation produced by experimental autoimmune
encephalomyelitis, in which immunization with a myelin
oligopeptide produces an anti-myelin T-cell response
[20-22]. Subsequently, a passive-transfer mouse model of
NMO involving intracranial injection of NMO-IgG and
human complement recapitulated key pathological find-
ings in NMO, including loss of AQP4 and glial fibrillary
acidic protein (GFAP) immunoreactivity, granulocyte and
macrophage infiltration, vasculocentric deposition of acti-
vated complement, and demyelination [23]. However, due
in part to the limited diffusion of AQP4-IgG and comple-
ment from the injection site, pathology in this model was
confined to a small region around the injection site, spar-
ing the optic nerves.
The purpose of this study was to establish an animal
model of NMO ON involving passive transfer of NMO-
IgG with targeted delivery to the optic nerves. Mice were
chosen for these studies because of the availability of
relevant knockout strains (AQP4 and CD59). After test-
ing various approaches we established the conditions in
which delivery of NMO-IgG to optic nerves produced
ON with characteristic NMO pathology.
Methods
Mice
In vivo studies were performed on 8- to 10-week-old,
weight-matched AQP4+/+ and AQP4−/− mice in CD1 gen-
etic background, which were generated as described previ-
ously [24]. Some experiments were done on CD59+/+ and
CD59−/− mice on a C57bl/6 background (provided by Dr
Xuebin Qin, Harvard University, USA). Littermates were
used as wild-type controls for the AQP4 and CD59 knock-
out mice. Mice were maintained in air-filtered cages and
fed normal mouse chow in the University of California,
San Francisco (UCSF) Animal Care facility. All procedures
were approved by the UCSF Committee on Animal
Research.
Neuromyelitis optica (anti-aquaporin-4) antibodies
Recombinant monoclonal NMO antibody rAb-53 (referred
to as NMO-IgG) was generated from a clonally expanded
plasma blast population from cerebrospinal fluid of an
NMO patient, as described and characterized previously
[22,25]. Purified rAb-53 was used for studies here because
of its high affinity for AQP4, and to eliminate the potential
variability introduced by using NMO patient serum,
which is polyclonal and may contain other antibodies
or soluble factors that influence NMO pathogenesis.
A NMO ‘superantibody’ with enhanced complement-
dependent cytotoxicity (referred as NMO-IgGCDC+)
was generated as described previously [26] by introducing
mutations (G236A/S267E/H268F/S324T/I332E) in the Fc
portion of rAb-53 [27].Neuromyelitis optica immunoglobulin G antibody
delivery to anterior optic nerve and retina
Adult mice were anesthetized with intraperitoneal tribro-
moethanol (avertin, 250 to 500 mg/kg). Lateral canthot-
omy was done under a dissecting microscope. Ocular
muscles were retracted and anterior optic nerve was ex-
posed to infuse locally 1 μg NMO-IgG and 0.5 μL human
complement (Complement Technology, Tyler, TX, USA)
in a total volume of 1.5 μL. For intravitreal injection, a 32-
gauge needle attached to a 10-μL gas-tight Hamilton
syringe was passed through the sclera, next to the lim-
bus, into the vitreous cavity. NMO-IgG (1 or 3 μg) and
0.5 μL human complement in a total volume of 2 μL
was injected (0.5 μL per minute) above the optic nerve
head.Neuromyelitis optica immunoglobulin G antibody
delivery to posterior optic nerve
Adult mice were anesthetized and mounted on a stereo-
taxic frame. A midline scalp incision was made and a burr
hole of diameter 1 mm was drilled in the skull 1-mm right
and 1-mm anterior to bregma. For single administration
of NMO-IgG, a 30-gauge needle attached to a 50-μL gas-
tight syringe was inserted through the brain (6 mm
below the dura down to base of the skull) near the
optic chiasm to deliver 5 μg NMO-IgG and 5 μL human
complement in a total volume of 10 μl. For continuous
administration of NMO-IgG, an osmotic minipump
(Alzet 1003D, Cupertino, Ca, USA) delivered 3.3 μg
NMO-IgG and 16.7 μL human complement per day
for 3 days.Immunofluorescence
Optic nerves were post-fixed for 2 hours in 4% parafor-
maldehyde. Ten micrometer-thick frozen sections were
immunostained at room temperature for 1 hour with
antibodies against AQP4 (1:200, Santa Cruz Biotechnology,
Santa Cruz, CA, USA), GFAP (1:100, Millipore, Temecula,
CA, USA), myelin basic protein (MBP; 1:200, Santa Cruz
Biotechnology), ionized calcium-binding adaptor molecule-1
(Iba1; 1:1,000; Wako, Richmond, VA, USA), albumin
(1:200, Santa Cruz Biotechnology), C5b-9 (1:100, Santa
Cruz Biotechnology), neutrophil (Ly-6G, 1:100, Santa
Cruz Biotechnology), eosinophil (siglec-F, 1:50, BD Biosci-
ences, Oxford, UK), macrophage (F4/80, 1:100, Santa
Cruz Biotechnology) or CD45 (1:10, BD Biosciences)
followed by the appropriate fluorescent secondary
antibody (1:200, Invitrogen, Grand Island, NY, USA).
Immunofluorescence was examined with a Leica (Wetzlar,
Germany) DM 4000 B microscope or Nikon (Melville,
NY, USA) laser-scanning confocal microscope. Areas were
defined by hand and quantified using ImageJ software
(National Institutes of Health).
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Retinal ganglion cells (RGCs) were labeled as described
previously [28-30]. Briefly, mice were injected with 1 μL
neurotracer dye FluoroGold (4% solution in saline;
Fluorochrome, Denver, CO, USA) in the superior col-
liculus (from the bregma, anterior-posterior, -3 mm;
medial-lateral, +0.5 mm; 2 mm below the dura) 7 days
before NMO-IgG and human complement delivery to
posterior optic nerve. Retinas were flattened 14 days
after the FluoroGold injection and whole-mounts were
fixed in 4% paraformaldehyde. RGCs were counted
manually under a fluorescence microscope with a 40×
objective. A total of 16 to 20 images per retina were used
for cell counting. As a positive control for RGC loss,
optic nerve crush injury was produced by 30-second
compression of the optic nerve 2 mm posterior to the
globe insertion using cross-action forceps. The optic
nerve was accessed by lateral canthotomy and dissection
beneath the lateral rectus. RGCs were quantified 7 days
after crush.
Statistical analysis
Values are presented as mean ± SEM. Comparisons be-
tween two groups were performed using the unpaired
Student's t-test. P < 0.05 was considered statistically
significant.
Results
Passive transfer of neuromyelitis optica immunoglobulin
G antibody and complement via retrobulbar infusion,
intravitreal injection or single perichiasmal injection does
not produce optic neuritis
Motivated by the success in creating NMO pathology in
mouse brain by passive transfer of NMO-IgG and hu-
man complement by intracerebral injection [23], sev-
eral approaches were tried to create ON or retinal
cytotoxicity in mice. We first delivered NMO-IgG and
complement to the anterior optic nerve by injection
approximately 2 mm lateral to the anterior optic nerve
following its exposure by lateral canthotomy. Figure 1A
shows strong AQP4 expression in the anterior optic
nerve, but only extradural deposition of NMO-IgG in
surrounding skeletal muscle and soft tissue, as revealed
using a fluorescently labeled anti-human secondary
antibody (NMO-IgG is a human antibody). Attempts
to increase contact time by using viscous gel vehicles
were also unsuccessful in allowing access of NMO-IgG
to optic nerve tissue, probably because of its dural en-
sheathment anterior to the optic canal.
We next tested intravitreal injection of NMO-IgG and
complement to evaluate the potential for direct retinal
injury, as AQP4 is strongly expressed on retinal Müller
cells [31], and NMO-associated retinal abnormalities
have been described [32-34]. As shown in Figure 1B,NMO-IgG binding to the AQP4-expressing retinal Müller
cells was detected with a secondary anti-human antibody.
No binding of a control (non-NMO) IgG was seen. How-
ever no pathology was observed in the retina as judged
by preserved AQP4 immunofluorescence (Müller cell
marker), absence of CD45-positive inflammatory cells,
and deposition of activated complement (C9neo im-
munostaining) (not shown). Also, NMO-IgG staining
was absent in the optic nerve. We speculate that the
absence of retinal pathology may be due to limited ac-
cess of intravitreally injected complement proteins be-
yond the inner blood-retina barrier to Müller cells
and/or their inactivation by soluble inhibitors of com-
plement in vitreous fluid or retinal tissue.
Reasoning that the posterior optic nerve and optic chi-
asm lack the dura that encases the anterior optic nerve,
we tested the delivery of NMO-IgG and complement by
a single injection near the optic chiasm by an intracra-
nial route, using stereotaxic methodology and a head-
bobbing sign to indicate needle contact with the cranial
floor underlying the optic chiasm/posterior nerves (see
Methods). The accuracy of needle placement was con-
firmed in preliminary studies in which dye-containing
gels were injected and the optic nerves visualized follow-
ing craniectomy. Figure 1C shows staining of the optic
nerve periphery with NMO-IgG, with no staining by a
control (non-NMO) IgG. While brain parenchyma near
the optic nerve showed marked NMO pathology, little
or no optic nerve pathology was seen, as evidenced by
preservation of AQP4, GFAP and MBP (myelin) im-
munofluorescence, and absence of CD45-positive infil-
trating leukocytes (not shown).
Continuous perichiasmal infusion of neuromyelitis optica
immunoglobulin G antibody and complement produces
neuromyelitis optica optic neuritis
We speculated that the absence of NMO pathology fol-
lowing a single perichiasmal injection of NMO-IgG and
complement may be related to minimal contact time of
the injected macromolecules with the optic nerve, as
their diffusion in brain extracellular space is likely much
faster than along the parallel white matter tracts of the
optic nerve [35,36]. In order to promote sustained optic
nerve exposure, NMO-IgG and complement were deliv-
ered continuously over 3 days using an implanted mini-
pump with needle tip placement near the optic chiasm.
Figure 2A shows Evan’s blue dye distribution following
3-days mini-pump infusion, which includes areas of pos-
terior prechiasmal optic nerves, optic chiasm, optic tract
and surrounding brain parenchyma. Figure 2B shows
NMO-IgG binding to AQP4 in the brain parenchyma
surrounding the needle tract. Figure 2C,D shows sub-
stantial NMO-IgG deposition in optic nerves, with focal
loss of AQP4 immunoreactivity, cell infiltration, and
Figure 1 Passive transfer of neuromyelitis optica immunoglobulin G antibody and complement via retrobulbar infusion, intravitreal
injection or single perichiasmal injection does not produce optic neuritis. (A) (Top) Lateral canthotomy was done in mice to expose the
optic nerve (arrow). (Bottom) Absence of binding of neuromyelitis optica immunoglobulin G antibody (NMO-IgG) (as seen using an anti-human
secondary antibody) to aquaporin-4 (AQP4) in the optic nerve (dashed line) 3 days after retrobulbar infusion of NMO-IgG and human complement
(representative of three eyes from separate mice). (B) Binding of NMO-IgG to AQP4 in retina (dashed line) after intravitreal injection. No binding was
seen with a control (non-NMO) IgG (n = 5 eyes). (Insert) Magnified view of NMO-IgG binding to AQP4 at perivascular end-feet of inner retinal Müller
cells. (C) Binding of NMO-IgG (and not of control IgG) to AQP4 after single perichiasmal injection. Despite efficient binding of NMO-IgG to AQP4
in (B) and (C), no pathology was observed after 3 days (n = 5 eyes).
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NMO-IgG and complement to the optic nerve, with
development of NMO-like pathology. No lesions were
seen following infusion of a control IgG and human
complement.
Optic nerves were analyzed in 12 mice receiving a
3-day infusion of NMO-IgG and complement and 10
mice receiving the same quantity of control (non-
NMO) IgG and complement. Eight out of 12 mice
receiving NMO-IgG and complement showed charac-
teristic NMO pathology in the optic nerve, with focal
reductions in AQP4, GFAP, MBP and neurofilamentimmunofluorescence (Figure 3A). The precise site of
the pathology was variable, likely reflecting slight
variation in the location of the needle tip. None of the
10 mice receiving control IgG and complement devel-
oped pathology, nor did any of five mice receiving
NMO-IgG alone (not shown), or of five AQP4 knockout
mice receiving NMO-IgG and complement (Figure 3A).
Development of optic nerve pathology therefore requires
NMO-IgG and complement, as well as AQP4 expression.
Based on the central role of complement in NMO
pathogenesis, we reasoned that increased complement
activity would result in more profound optic nerve
Figure 2 Continuous perichiasmal infusion of neuromyelitis optica immunoglobulin G antibody and complement leads to aquaporin-4
loss and complement activation in optic nerve. (A) (Left) Three-day continuous intracranial perichiasmal infusion of neuromyelitis optica
immunoglobulin G antibody (NMO-IgG) and human complement was done by implantation of an osmostic pump. (Right) Area of diffusion in
optic chiasm and brain of an infused blue dye (dashed line). (B) Immunofluorescence showing binding of NMO-IgG to aquaporin-4 (AQP4) in
brain around the needle tract (white line) at 3-days after infusion of NMO-IgG or control IgG and complement. (C) AQP4 immunofluorescence,
hematoxylin and eosin (H&E) staining and NMO-IgG immunofluorescence of the optic nerve. Dashed lines show lesion or area of NMO-IgG deposition.
(D) Immunofluorescence showing AQP4 loss, NMO-IgG deposition and complement activation (C5b-9, arrows) in the optic nerve after infusion
of NMO-IgG as in (A). White dashed lines demarcate the lesion.
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fer of a mutated recombinant NMO-IgG (NMO-IgGCDC+)
having ~10-fold increased complement effector function
[26]; and (b) infusion in mice lacking CD59, the major
membrane-associated complement inhibitor protein on
mouse astrocytes [37,38]. Robust and more widespread
NMO pathology was seen following 3-days infusion of
NMO-IgGCDC+ and complement in wild-type mice,
and of (non-mutated) NMO-IgG and complement in
CD59-null mice (Figure 3B).
One of the characteristics of NMO pathology is in-
flammatory cell infiltration. After 3-days infusion with
NMO-IgG or NMO-IgGCDC+ and complement, optic
nerves showed inflammatory cell infiltration on hematoxylin
and eosin staining (Figure 3C), mainly mononuclear inflam-
matory cells. Inflammatory cell infiltration was not seen with
control IgG with complement, NMO-IgGCDC+ alone, orNMO-IgG with complement in AQP4−/− mice (data not
shown).
Characterization of optic neuritis pathology produced by
infusion of neuromyelitis optica immunoglobulin G
antibody
The characteristic features of NMO pathology include
AQP4, GFAP, myelin loss and inflammatory cell infiltra-
tion, as shown above, as well as BBB disruption, and in-
flammation with microglial activation and macrophage
and granulocyte infiltration [6-8]. Figure 4A shows focal
albumin extravasation in areas of NMO pathology, dem-
onstrating BBB leakage. Localized inflammation was also
evident with increased Iba1 (microglial marker) and
CD45 (leukocyte) immunofluorescence (Figure 4A).
Albumin extravasation and inflammation were absent in
mice receiving a 3-day infusion of control IgG and
Figure 3 Continuous perichiasmal infusion of neuromyelitis optica immunoglobulin G antibody and complement produces
complement-dependent, neuromyelitis optica-like optic neuritis. (A) (Top) Micrographs showing aquaporin-4 (AQP4), glial fibrillary acidic
protein (GFAP), myelin basic protein (MBP) and neurofilament (NF) immunoreactivity in the optic nerve after 3-days continuous perichiasmal
infusion of complement with neuromyelitis optica immunoglobulin G antibody (NMO-IgG) or control IgG in wild-type mice and NMO-IgG in
AQP4−/− mice. White dashed line demarcates area with loss of immunofluorescence. (Bottom) Higher magnification of yellow boxes. (B)
(Top) AQP4, GFAP, MBP and NF immunofluorescence in the optic nerve after 3-days continuous perichiasmal infusion of (left) NMO-IgGCDC+
with or without complement in wild-type mice or (right) complement with control IgG or NMO-IgG in CD59−/− mice. White dashed line demarcates
region with loss of immunofluorescence. (Bottom) Higher magnification of yellow boxes. (C) Hematoxylin and eosin staining of the optic nerve
after 3-days continuous perichiasmal infusion in wild-type mice of control IgG or NMO-IgG or NMO-IgGCDC+, with or without complement.
HC, human complement.
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NMO-IgGCDC+ and complement, and in CD59-null mice
receiving NMO-IgG and complement.
The composition of the CD45-positive cell infiltrate
was determined using antibodies against cell-specific
markers. Figure 4B shows positive immunofluorescence
for macrophages (F4/80), eosinophils (Siglec-F) and neu-
trophils (Ly-6G), with quantification showing a greaternumber of macrophages than granulocytes in this model.
Cell-specific immunofluorescence was absent in mice re-
ceiving a 3-day infusion of control IgG and complement.
Retinal ganglion cell loss
A consequence of NMO ON is retrograde RGC loss lead-
ing to visual deficit. We quantified RGC number in
whole-retina mounts at 7 days after delivery of NMO-IgG
Figure 4 Inflammation in optic nerve lesions. (A) Immunostaining for albumin, ionized calcium-binding adaptor molecule-1 (Iba1); microglia
and CD45 (leukocytes) in the optic nerve after 3-days continuous perichiasmal infusion of neuromyelitis optica immunoglobulin G antibody
(NMO-IgG) and complement. (B) (Left) Immunostaining with markers for macrophages, neutrophils and eosinophils. (Right) Number of infiltrating
cells of each per 0.01 mm2 (mean ± SEM, n = 3).
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(Figure 5A). Figure 5B,C shows no clear reduction in
the number of RGCs in mice receiving a 3-day infusion of
NMO-IgG and complement compared to control IgG.
RGC number was reduced by 28% in wild-type mice ad-
ministered NMO-IgGCDC+ and complement and by 21%
in CD59−/− mice injected with NMO-IgG. No RGC loss
was seen in AQP4−/− mice injected with NMO-IgG. Optic
nerve crush injury was used as a positive control of RGC
damage.
Discussion
Current understanding of NMO pathogenesis comes
largely from data on brain and spinal cord, as there is lit-
tle descriptive pathology of optic nerves in human NMO
and adequate animal models of NMO ON have not beendeveloped. The bulk of evidence supports a pathogenesis
mechanism that involves NMO-IgG access to the central
nervous system and binding to AQP4 on astrocytes,
which causes complement- and cell-mediated cytotox-
icity [22,26,39-42]. The primary astrocyte damage initi-
ates an inflammatory reaction with cytokine release,
granulocyte and macrophage infiltration, and further
BBB disruption, which produces secondary oligodendro-
cyte injury, demyelination and neuron loss. This mech-
anism is supported by pathology in human spinal cord
and brain [43,44], by brain pathology in mice following
passive transfer of NMO-IgG by intracerebral injection
[23], and by ex vivo studies in spinal cord slice cultures
exposed to NMO-IgG and various effector molecules
and cells [45]. It has been assumed without direct evi-
dence that a similar pathogenesis mechanism applies to
Figure 5 Continuous perichiasmal infusion of neuromyelitis optica immunoglobulin G antibody and complement produces retinal
ganglion cells loss. (A) Retrograde labeling of retinal ganglion cells (RGCs) by injection of FluoroGold in the superior colliculus. After 7 days,
neuromyelitis optica immunoglobulin G antibody (NMO-IgG) and complement were infused near the optic chiasm by minipump. Retinas were
collected 7 days later. (B) Micrographs showing RGC loss. (C) Quantification of RGC number per 0.06 mm2 microscope field (mean ± SEM,
n = 4, *P < 0.001). AQP4, aquaporin-4; HC, human complement; (ON, optic nerve).
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exposed to NMO-IgG and complement showed an
astrocytopathy with demyelination, but this model is
limited by the short-term (~1 day) viability of optic
nerve cultures [45].
The main finding of the study here is that passive
transfer of NMO-IgG and human complement to mice
by continuous intracranial infusion near the optic chi-
asm produces optic nerve lesions with loss of AQP4 and
GFAP immunoreactivity, demyelination, and inflamma-
tion with prominent macrophage infiltration. Optic
nerve pathology was exacerbated when NMO-IgG was
administered to CD59 knockout mice or when a mu-
tated NMO antibody with enhanced complement ef-
fector function was administered to wild-type mice,
supporting a central role of complement in NMO ON in
our model. Control studies, including infusions in AQP4
knockout mice, indicated that the pathological changes
require NMO-IgG, complement and AQP4. The passive
transfer model of NMO ON established here should be
useful in studying mechanisms of NMO pathogenesis
specific to the anterior visual pathway, as well as in
evaluating potential vision-preserving therapies using
clinically relevant in vivo anatomic and functional out-
come measures.
Prior models of general neuroinflammation include optic
nerve pathology, though the pathogenesis mechanisms arevery different from that of NMO, which involves a humo-
rally mediated astrocytopathy. As mentioned in the Intro-
duction, ON is a well-described feature of experimental
autoimmune encephalomyelitis. ON has also been seen in
a subpopulation of transgenic mice expressing myelin
oligodendrocyte glycoprotein (MOG)-specific T cell recep-
tors [46]. Crossing this mouse with a MOG-specific Ig
heavy-chain knock-in mouse produced mice with both T
and B cell MOG reactivity [29]. This double transgenic
mouse manifests selective optic nerve and spinal cord
pathology (with 60% penetrance) and a Th17 differenti-
ation bias, reminiscent of NMO [47]. While ON is seen in
these various models, they are probably not useful to
study NMO pathogenesis mechanisms or test NMO
therapeutics.
Several approaches to deliver NMO-IgG and comple-
ment were tested to produce robust ON in mice. Deliv-
ery of NMO-IgG and complement to the anterior optic
nerve following lateral canthotomy did not produce
optic nerve pathology, probably because of limited
access of infused macromolecules to the ensheathed
anterior optic nerve. Though intravitreal injection of
NMO-IgG and complement resulted in NMO-IgG bind-
ing to AQP4 in retinal Müller cells, no retinal pathology
was seen, perhaps because of limited access of some
complement components to inner retinal layers. Also,
intravitreally delivered solutes and macromolecules are
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studies, we postulated that delivery of NMO-IgG and
complement near the unsheathed perichiasmal posterior
optic nerve might produce NMO ON. Though a single
intracerebral injection of NMO-IgG and complement
with the needle tip near the optic chiasm resulted in
some NMO-IgG binding to optic nerve, as well as NMO
pathology in brain near the optic nerve, little NMO
pathology was found. Robust NMO pathology required con-
tinuous intracerebral injection of NMO-IgG and comple-
ment near the optic nerve. We conclude that the sustained
exposure of target tissues to pathogenic macromolecules
afforded by continuous infusion better recapitulates human
NMO in which progressive pathology involves an
amplifying cycle of astrocyte cytotoxicity, inflammation
and BBB disruption. We cannot exclude, however, the
possibility that the prechiasmal optic nerve and optic
chiasm may be more susceptible to NMO-IgG-mediated
pathology than the anterior optic nerve.
Though the NMO ON model developed here pro-
duced robust lesions with characteristic NMO path-
ology, there are a number of limitations of the model
and potential directions for future advances. Continuous
intracerebral infusion with precise needle placement is
invasive and technically challenging. The direct adminis-
tration of human complement, which was necessary be-
cause of the weak activity of mouse complement and the
presence of complement inhibitory factor(s) in mouse
serum [48], does not accurately recapitulate the human
disease in which endogenous complement proteins de-
rive primarily from the serum. We recently established a
rat model of NMO involving intracerebral administra-
tion of NMO-IgG without added complement, which
produced robust NMO pathology in brain around the
needle track [16]. Pathology required active rat comple-
ment, as complement inactivation by cobra venom factor
prevented the astrocyte cytotoxicity and demyelination.
In a recent variation of the rat model, NMO pathology
was produced in brain by peripheral NMO-IgG ad-
ministration and focal mechanical BBB disruption
(Asavapanumas and colleagues, unpublished results).
Models of NMO ON in rats involving peripheral or
optic nerve-targeted NMO-IgG delivery, perhaps in
combination with maneuvers to disrupt the blood-optic
nerve barrier, may produce ON without the need to
administer complement.
It remains unclear why NMO pathology is primarily
restricted to optic nerve and spinal cord, and to a lesser
extent in brain, with little or no pathology in peripheral
AQP4-expressing tissues. Optic nerve susceptibility in
NMO is unlikely due solely to NMO-IgG access, and
may involve impaired diffusion of NMO-IgG, soluble
pro-inflammatory factors and complement proteins from
focal areas of central nervous system entry. Optic nervesusceptibility in NMO might also arise from the high
AQP4 expression in the optic nerve compared to brain
[47] and the abundance of large orthogonal arrays of
particles in perivascular astrocytic end-feet of the optic
nerve [49-51] that promote tight binding of AQP4-IgG
and efficient CDC [52]. Plasmablasts in the cerebro-
spinal fluid secreting NMO-IgG locally [22] and/or re-
gional variations in the expression of complement
regulator or key BBB proteins may also play a role.
Conclusions
Passive transfer of NMO-IgG, when supplemented with
human complement, produced ON in mice with charac-
teristic NMO pathology. Development of robust path-
ology required continuous exposure of the posterior
optic nerve to NMO-IgG and complement, which was
accomplished by 3-days intercerebral infusion using an
implanted mini-pump with needle positioned near the
optic chiasm. Our data show that, as found in brain, pas-
sive transfer of NMO-IgG and complement is sufficient
to produce ON in mice. NMO ON models should be
useful in testing novel disease-modifying therapeutics
aimed at preserving vision.
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